PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
MSI-H is a biomarker for solid tumors benefiting from immunotherapy. Recent clinical studies
have confirmed that PD-1 inhibitors have a good effect on MSI-H advanced colorectal cancer
for first- or second-line treatment. The overall effective rate is 30% to 40%. However, about
30% of patients are resistant to PD-1 inhibitors. Whether PD-1 inhibitors and existing
chemotherapeutics and anti-vascular drugs have synergistic effects is worth studying. This
study is a phase II prospective clinical study of PD-1 inhibitor combined with bevacizumab
and FOLFIRI regimen in the second-line treatment of unresectable recurrent or metastatic
MSI-H colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital